Loading…
Sun Pharma Advanced Research Company (SPARC)₹210.80+6.99%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Sun Pharma Advanced Research Company reported sales of ₹40.01 Cr, up 299.7% from Jun 2025, and net profit of −₹21.03 Cr. For the year to Mar 2026, sales were ₹1,882 Cr and net profit ₹1,556 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.01 | 14.01 | 17.01 | 17.01 | 13.01 | 15.02 | 27.03 | 10.01 | 8.01 | 8.01 | 1,856 | 40.01 |
| Expenses | 113 | 116 | 122 | 110 | 116 | 88.73 | 79.78 | 61.81 | 73.77 | 64.79 | 79.84 | 73.82 |
| Operating Profit | −91.04 | −103 | −106 | −93.07 | −103 | −74.05 | −53.02 | −52.07 | −66.07 | −57.05 | 1,774 | −34.06 |
| OPM % | −432.1% | −740.1% | −639.1% | −555.0% | −800.1% | −494.1% | −196.1% | −540.0% | −836.1% | −670.1% | 95.9% | −85.1% |
| Other Income | 8.01 | 6.01 | 4.01 | 2.01 | 0.00 | 0.00 | 0.00 | 9.01 | 0.00 | −12.01 | 2.01 | 23.99 |
| Interest | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 3.01 | 5.01 | 6.01 | 8.02 | 9.02 | 12.01 | 8.01 |
| Depreciation | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 2.01 | 2.01 |
| Profit before tax | −86.11 | −100 | −105 | −96.08 | −107 | −79.03 | −61.06 | −52.02 | −76.02 | −80.09 | 1,762 | −21.03 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | −1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −12.02 | 0.00 | 0.00 |
| Net Profit | −86.08 | −100 | −106 | −96.22 | −107 | −80.12 | −60.12 | −52.10 | −76.15 | −80.18 | 1,765 | −21.03 |
| EPS (Rs) | −2.67 | −3.08 | −3.27 | −2.97 | −3.32 | −2.46 | −1.85 | −1.61 | −2.35 | −2.49 | 54.48 | −0.65 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 239 | 76.04 | 72.08 | 1,882 | 1,912 |
| Expenses | 451 | 477 | 394 | 279 | 292 |
| Operating Profit | −214 | −402 | −323 | 1,600 | 1,617 |
| OPM % | −90.1% | −532.1% | −450.1% | 84.9% | 84.6% |
| Other Income | 10.99 | 29.03 | 2.01 | −2.01 | 13.99 |
| Interest | 8.01 | 2.01 | 9.01 | 34.01 | 37.06 |
| Depreciation | 12.03 | 13.04 | 12.04 | 10.04 | 10.04 |
| Profit before tax | −223 | −387 | −343 | 1,554 | 1,585 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Exceptional items | 0.00 | 1.01 | 0.00 | −12.01 | −12.02 |
| Net Profit | −223 | −387 | −344 | 1,556 | 1,587 |
| EPS (Rs) | −6.88 | −11.96 | −10.59 | 48.05 | 48.99 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 31.86 | 31.90 | 31.90 | 31.87 |
| Reserves | 480 | 93.03 | −249 | 1,303 |
| Borrowings | 16.01 | 61.18 | 269 | 558 |
| Other Liabilities | 301 | 327 | 283 | 272 |
| Total Liabilities | 828 | 514 | 335 | 2,165 |
| Fixed Assets | 106 | 108 | 98.69 | 84.66 |
| CWIP | 27.01 | 44.01 | 54.01 | 71.97 |
| Investments | 290 | 1.99 | 0.00 | 0.00 |
| Other Assets | 405 | 361 | 183 | 2,009 |
| Trade receivables | 32.94 | 15.97 | 15.96 | 7.98 |
| Cash & equivalents | 112 | 155 | 2.01 | 1.01 |
| Total Assets | 828 | 514 | 335 | 2,165 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | −69.22 | −430 | −361 | −240 |
| Cash from investing activity | −547 | 391 | 158 | −22.95 |
| Cash from financing activity | 618 | 42.05 | 199 | 261 |
| Net cash flow | −1.01 | 5.02 | −3.01 | −1.01 |
| Capex | 15.35 | 26.44 | 10.31 | 23.74 |
| Free cash flow | −83.78 | −454 | −369 | −261 |
| CFO / OP % | 35.0% | 106.0% | 114.0% | −17.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 50 | 75 | 82 | 2 |
| Cash conversion cycle | 51 | 76 | 83 | 3 |
| Working capital days | −193 | −738 | −1,780 | 215 |
| ROCE % | — | −107.9% | −278.9% | 164.1% |
For the Jun 2026 quarter, Sun Pharma Advanced Research Company reported sales of ₹40.01 Cr, up 299.7% year on year and net profit of −₹21.03 Cr. The operating margin was −85.1%.
Sun Pharma Advanced Research Company's sales for the year to Mar 2026 were ₹1,882 Cr; over the last twelve months they were ₹1,912 Cr.
Net profit for the year to Mar 2026 was ₹1,556 Cr, and ₹1,587 Cr over the last twelve months. Earnings per share over the same trailing period were ₹48.99.
Sun Pharma Advanced Research Company reported borrowings of ₹558 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.
Cash from operations was −₹240 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹261 Cr.